Cargando…
Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era
The prognostic value of pretreatment serum beta-2 microglobulin (B2MG) level in advanced Hodgkin lymphoma (HL) patients treated in the modern era has not been well established. We conducted a retrospective study involving 202 advanced classical HL (cHL) patients treated from 1998.5 to 2015.7 to eval...
Autores principales: | Wang, Qin, Qin, Yan, Zhou, Shengyu, He, Xiaohui, Yang, Jianliang, Kang, Suyi, Liu, Peng, Yang, Sheng, Zhang, Changgong, Gui, Lin, Sun, Yan, Shi, Yuankai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342156/ https://www.ncbi.nlm.nih.gov/pubmed/27750215 http://dx.doi.org/10.18632/oncotarget.12663 |
Ejemplares similares
-
Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era
por: Chen, Haizhu, et al.
Publicado: (2022) -
Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type
por: Dai, Wumin, et al.
Publicado: (2017) -
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma
por: Shi, Yuankai, et al.
Publicado: (2015) -
Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
por: Jiang, Shiyu, et al.
Publicado: (2020) -
Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)